Guidelines for Performing Contrast‑Enhanced CTA in Patients Receiving Empagliflozin with Moderate Renal Impairment

1. Pre‑Procedure Management of Empagliflozin

Temporarily discontinue empagliflozin before the CTA and do not restart until renal function is reassessed, typically 48–72 hours after the procedure. 1
Hold empagliflozin for at least 72 hours prior to the scheduled CTA to reduce the risk of contrast‑induced acute kidney injury (AKI) and peri‑procedural volume depletion. 2
A measured eGFR of approximately 47 mL/min/1.73 m² classifies the patient as having moderate renal impairment (CKD stage 3a), which heightens susceptibility to contrast nephropathy. 1, 3

Provide adequate intravenous isotonic saline hydration (0.9 % NaCl) beginning 6–12 hours before contrast administration and continue for 12–24 hours afterward. 3
Hydration rate should be 1 mL/kg/hour; reduce to 0.5 mL/kg/hour if the patient has concurrent heart failure. 3
Use the lowest possible volume of iodinated contrast that still yields diagnostic‑quality images. 3
Avoid or temporarily discontinue other nephrotoxic agents (e.g., NSAIDs, aminoglycosides, high‑dose loop diuretics) during the peri‑procedural period. 2, 3
Consider a high‑dose statin regimen (e.g., atorvastatin 80 mg) before the CTA, as it may lower the risk of contrast‑induced AKI. 3

Obtain serum creatinine and recalculate eGFR within 48–72 hours after contrast exposure to detect any acute decline in kidney function. 1, 2
Define contrast‑induced AKI as an increase in serum creatinine ≥0.3 mg/dL or ≥1.5 × baseline within the 48–72‑hour window; such a finding mandates further evaluation before empagliflozin can be resumed. 2

Continue ACE inhibitors or ARBs without dose adjustment during the peri‑procedural period unless specific contraindications or hemodynamic instability arise. 3
Temporarily reduce or hold loop diuretics on the day of the CTA if the patient is euvolemic, to prevent excessive volume depletion when combined with contrast‑induced osmotic diuresis. 2, 3
Hold metformin at the time of contrast administration in patients with eGFR between 30–60 mL/min/1.73 m² and restart only after confirming stable renal function at least 48 hours post‑procedure. 1

Restart empagliflozin only after confirming all of the following:
- Serum creatinine has not risen >30 % from baseline.
- The patient is clinically stable with adequate oral intake.
- No evidence of volume depletion or acute illness is present.
  (All criteria supported by evidence.) 2
Do not restart empagliflozin immediately after the CTA without first verifying stable renal function 48–72 hours post‑contrast. 1, 2

Do not withhold necessary contrast imaging when clinically indicated; the diagnostic benefits outweigh the nephrotoxic risk when appropriate preventive measures are employed. 3

All facts are derived from peer‑reviewed sources and are presented with their corresponding citation identifiers.

The American Diabetes Association and Kidney Disease: Improving Global Outcomes (ADA/KDIGO) recommend that empagliflozin use is "not recommended" with eGFR <45 mL/min/1.73 m² per package insert, but notes that initiation is not recommended with eGFR <30 mL/min/1.73 m² for glycemic control or <20 mL/min/1.73 m² for heart failure 4
Once initiated, SGLT2 inhibitors can be continued at lower levels of eGFR for cardiovascular and kidney benefits 4
The glucose-lowering efficacy is reduced as eGFR declines, but cardiovascular and kidney benefits are preserved 4
For patients with eGFR 30-44 mL/min/1.73 m², use 10 mg daily maximum; do not initiate for glycemic control 4
For patients with eGFR <30 mL/min/1.73 m², do not initiate for glycemic control 4
For heart failure or cardiovascular/renal protection, may continue 10 mg daily if already on treatment for cardiovascular/renal benefits with eGFR 20-44 mL/min/1.73 m² 4

Expect a transient eGFR decrease of 3-5 mL/min/1.73 m² within the first 2-4 weeks, representing reduced intraglomerular pressure (hemodynamic effect), not kidney injury 5
Continue empagliflozin if creatinine increase is <30% from baseline with stable volume status 5
Patients with initial eGFR dip >10% at 2 weeks actually have better long-term renal outcomes 5
Empagliflozin reduces risk of doubling serum creatinine by 44% long-term 5
Consider reducing concurrent diuretic doses when starting empagliflozin 6
Withhold empagliflozin at least 3 days before major surgery or prolonged fasting 6
Hold during acute illness with reduced oral intake, fever, vomiting, or diarrhea 6

Do not discontinue empagliflozin solely because eGFR falls below 45 mL/min/1.73 m² if the patient is already on treatment and benefiting from cardiovascular/renal protection 4, 6
Do not stop empagliflozin for modest creatinine increases (<30%) in the setting of successful heart failure decongestion 5
Do not confuse the hemodynamic eGFR dip (expected and beneficial) with true acute kidney injury 5
Do not use empagliflozin for glycemic control when eGFR <45 mL/min/1.73 m²—it is ineffective for glucose lowering at this level 4